Related Experiment Video

Updated: May 28, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

AKT2 Exon 3 Variants and Their Prevalence in Prostate Cancer Patients: Insights from a Jordanian Clinical Cohort

Nuseibah Rahahlah1, Zina Al-Alami1, Mohammed S Alorjani2

  • 1Department of Medical Laboratory Sciences, Faculty of Allied Medical Sciences, Al-Ahliyya Amman University, P.O. Box 115, Amman 19111, Jordan.

International Journal of Molecular Sciences
|May 27, 2026
PubMed

Insights

This study found 5.7% AKT2 gene mutations in Jordanian prostate cancer patients. These AKT2 variants may play a role in prostate cancer development, warranting further investigation.

Area of Science:

  • Genetics
  • Oncology
  • Molecular Biology

Background:

  • The AKT2 gene is crucial for cellular functions and its abnormalities are linked to tumor progression.
  • AKT2 plays a role in cell survival, growth, and therapy resistance.
  • AKT2 overexpression is associated with prostate cancer (PC) development, indicating its potential as a therapeutic target.

Purpose of the Study:

  • To determine the frequency and distribution of AKT2 gene variants in Jordanian men with PC.
  • To explore the association between AKT2 genetic variations and clinicopathological parameters in prostate cancer.

Main Methods:

  • DNA extraction from 123 formalin-fixed paraffin-embedded (FFPE) tissue samples of Jordanian prostate adenocarcinoma patients.
  • Polymerase chain reaction (PCR) amplification of AKT2 exon 3.
  • Sequencing of AKT2 exon 3 to identify genetic variations.

Main Results:

  • A prevalence of 5.7% for AKT2 mutations was observed in the studied Jordanian cohort.
  • Six distinct mutations were identified, including missense, synonymous, splice acceptor, and intron variants.
  • No significant correlation was found between AKT2 variants and clinicopathological parameters like age, tumor stage, PSA levels, or Gleason score.

Conclusions:

  • The identified prevalence of AKT2 mutations suggests a potential role in prostate cancer pathogenesis within the Jordanian population.
  • Further comprehensive genetic studies of the entire AKT2 gene and its downstream pathways are necessary.
  • Understanding AKT2's role can contribute to better insights into prostate cancer genetics and potential therapeutic strategies.
Keywords:
AKT2adenocarcinomagood health and wellbeingkinasemutationsprostate cancer

More Related Videos

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Related Concept Videos

Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...